Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06043674 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

A Phase 2 study of Chronic Lymphocytic Leukemia and Richter's Transformation, sponsored by Christine Ryan.

Recruiting
Registry status
Phase 2
Development phase
70
Enrollment target
5
Study locations

NCT06043674 is a Phase 2 study of Chronic Lymphocytic Leukemia and Richter's Transformation that is actively recruiting participants, run by Christine Ryan. The registered enrollment target is 70 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (61% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06043674, a Phase 2 study of Chronic Lymphocytic Leukemia and Richter's Transformation, is actively recruiting participants, sponsored by Christine Ryan.

RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
5
Study locations

Study Summary

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: * Glofitamab (a T-cell bispecific humanized monoclonal antibody) * Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) * Polatuzumab vedotin (an antibody-drug conjugate) * Pirtobrutinib (a selective inhibitor of BTK) * Atezolizumab (a humanized immunoglobulin monoclonal antibody) * Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)

Conditions Studied

Chronic Lymphocytic Leukemia Richter's Transformation

Interventions

  • DRUG Obinutuzumab
  • DRUG Glofitamab
  • DRUG Atezolizumab
  • DRUG Polatuzumab Vedotin
  • DRUG Tocilizumab

Study Locations (5)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Georgia

  • Winship Cancer Institute at Emory University - Atlanta

North Carolina

  • The University of North Carolina at Chapel Hill - Chapel Hill

Ohio

  • The Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2024-01-22
Est. Completion 2033-01-15
Phase Phase 2

Sponsor

Christine Ryan

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06043674

The ClinicalTrials.gov registry entry for NCT06043674 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (61% lower). The listed sponsor is Christine Ryan, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.

NCT06043674 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Georgia, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06043674 about?

NCT06043674 is a clinical study titled "Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation". This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in thi...

What is the current status of trial NCT06043674?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2024-01-22. Estimated completion is 2033-01-15.

What conditions does trial NCT06043674 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Richter's Transformation.

What interventions are being tested in trial NCT06043674?

The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Atezolizumab (DRUG), Polatuzumab Vedotin (DRUG), Tocilizumab (DRUG).

Who is sponsoring clinical trial NCT06043674?

This trial is sponsored by Christine Ryan, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06043674 being conducted?

This trial has 5 study locations across Georgia, Massachusetts, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Richter's Transformation

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.